Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India.
Location: India, Gujarat, Sarkhej
Employees: 5001-10000
Phone: +91 79 3983 7000
Total raised: $56.2M
Founded date: 1976
Investors 1
| Date | Name | Website |
| 13.05.2024 | ChrysCapit... | chryscapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.05.2012 | - | $56.2M | ChrysCapit... |
Mentions in press and media 21
| Date | Title | Description |
| 20.02.2026 | ChrysCapital inks $159 mn control deal for Novartis India, makes open offer | The Novartis logo at a building in Rotkreuz, Switzerland | Credit: Reuters/Arnd Wiegmann Homegrown private equity firm ChrysCapital has agreed to acquire Swiss pharmaceutical major Novartis AG’s entire stake in its Mumbai-listed unit for Rs... |
| 20.10.2025 | Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions | LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move... |
| 11.08.2025 | Intas & Accord signs Agreement to acquire Prothya Biosolutions | AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leadin... |
| 01.03.2025 | Motilal Oswal's Bold Bet on Megafine Pharma: A Strategic Move in the API Landscape | In a significant move that underscores the shifting dynamics of the pharmaceutical industry, Motilal Oswal Alternates (MO Alts) has acquired a majority stake in Megafine Pharma Pvt Ltd for ₹460 crore. This investment marks MO Alts' first ma... |
| 25.02.2025 | MO Alts picks up majority stake in API maker Megafine Pharma | Credit: Thinkstock Motilal Oswal Alternates (MO Alts), the private equity arm of Motilal Oswal Financial Services Ltd, has invested Rs 460 crore to acquire a majority stake in active pharmaceutical ingredient (API) manufacturing firm Megafi... |
| 13.02.2025 | The New Frontier of Competition: India’s Regulatory Landscape for Private Equity | The world of private equity is changing. No longer can investors wade through deals without a care. The Competition Commission of India (CCI) is on high alert. Its focus? Common ownership in rival firms. This shift reflects a global trend. ... |
| 12.02.2025 | What the CCI's concerns over common ownership mean for private equity deals | Anisha Chand (left) and Yatharth V. Singh, Khaitan & Co Gone are the days when private equity investments were considered entirely benign from an antitrust perspective. Over the last five years, the Competition Commission of India (CCI)... |
| 07.02.2025 | Henlius and Dr. Reddy's Partnership: A New Dawn for Biosimilars in Oncology | In the fast-paced world of biopharmaceuticals, partnerships can be the lifeblood of innovation. Recently, Shanghai Henlius Biotech, Inc. and Dr. Reddy's Laboratories forged a significant alliance that could reshape the landscape of oncology... |
| 05.02.2025 | Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC Serplulimab h... |
| 23.01.2025 | Kotak Alternate Asset hits first close of third life sciences-focused PE fund | Credit: 123RF.com Kotak Alternate Asset Managers Ltd, the alternative asset management arm of Kotak Mahindra Group, said Thursday it has marked the first close of its third healthcare and life sciences-focused private equity fund. The firm ... |
Show more